Use of vaccines as probes to define disease burden

The Lancet

Volumn 383, Issue 9930, 2014, Pages 1762-1770

  Feikin, Daniel R ^a,b   Scott, J Anthony G ^c,d   Gessner, Bradford D ^e  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e Agence de Médecine Préventive AMP   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

DENGUE; DISEASE BURDEN; DISEASE COURSE; DRUG USE; HUMAN; INFLUENZA; MALARIA; MEDICAL RESEARCH; MORBIDITY; PRIORITY JOURNAL; REVIEW; ROTAVIRUS; STREPTOCOCCUS PNEUMONIAE; TYPHOID FEVER; HAEMOPHILUS INFLUENZAE TYPE B; INFECTION PREVENTION;

COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; COST OF ILLNESS; DEVELOPING COUNTRIES; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; ROTAVIRUS INFECTIONS; VACCINES; VIRAL VACCINES;

EID: 84900819513     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61682-7     Document Type: Review

References (52)

1. Mulholland EK. Use of vaccine trials to estimate burden of disease. J Health Popul Nutr 2004; 22: 257-67.
2. Mulholland K, Levine O, Nohynek H., Greenwood BM Evaluation of vaccines for the prevention of pneumonia in children in developing countries. Epidemiol Rev 1999; 21: 43-55.
3. Bale JR. Creation of a research program to determine the etiology and epidemiology of acute respiratory tract infection among children in developing countries. Rev Infect Dis 1990; 12 (suppl 8): S861-66.
4. Mulholland K, Hilton S, Adegbola R., et al Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997; 349: 1191-97.
5. Bennett JV, Platonov AE, Slack M.P., Mala P., Burton AH, Robertson SE Haemophilus influenzae type b (Hib) meningitis in the pre-vaccine era: a global review of incidence, age distribution, and case-fatality rates. Geneva: World Health Organization, 2002.
6. Gessner BD, Sutanto A, Linehan M., et al Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial. Lancet 2005; 365: 43-52.
7. Gessner BD, Sedyaningsih ER, Griffiths U.K., et al Vaccine-preventable Haemophilus influenza type B disease burden and cost-effectiveness of infant vaccination in Indonesia. Pediatr Infect Dis J 2008; 27: 438-43.
8. Viviani S, Carrieri P, Bah E., et al, and the Gambia Hepatitis Intervention Study. 20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 3216-23.
9. Qureshi H, Gessner BD, Leboulleux D, Hasan H., Alam SE, Moulton LH The incidence of vaccine preventable influenza-like illness and medication use among Pakistani pilgrims to the Haj in Saudi Arabia. Vaccine 2000; 18: 2956-62.
10. Daza P, Banda R, Misoya K., et al The impact of routine infant immunization with Haemophilus influenzae type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus prevalence. Vaccine 2006; 24: 6232-39.
11. Lewis RF, Kisakye A, Gessner B.D., et al Action for child survival: elimination of Haemophilus influenzae type b meningitis in Uganda. Bull World Health Organ 2008; 86: 292-301.
12. Muganga N, Uwimana J, Fidele N., et al Haemophilus influenzae type b conjugate vaccine impact against purulent meningitis in Rwanda. Vaccine 2007; 25: 7001-05.
13. Tate JE, Curns AT, Cortese M.M., et al Burden of acute gastroenteritis hospitalizations and emergency department visits in US children that is potentially preventable by rotavirus vaccination: a probe study using the now-withdrawn rotashield vaccine. Pediatrics 2009; 123: 744-49.
14. Cutts FT, Zaman SM, Enwere G, et a.l., and the Gambian Pneumococcal Vaccine Trial Group. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005; 365: 1139-46.
15. Klugman KP, Madhi SA, Huebner R.E., Kohberger R., Mbelle N, Pierce N, and the Vaccine Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349: 1341-48.
16. Lagos R, Horwitz I, Toro J., et al Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. Pediatr Infect Dis J 1996; 15: 216-22.
17. Levine OS, Lagos R, Muñoz A, et al Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b. Pediatr Infect Dis J 1999; 18: 1060-64.
18. Cherian T, Mulholland EK, Carlin J.B., et al Standardized interpretation of paediatric chest radiographs for the diagnosis of pneumonia in epidemiological studies. Bull World Health Organ 2005; 83: 353-59.
19. Black S, Shinefield H, Fireman B., et al, and the Northern California Kaiser Permanente Vaccine Study Center Group. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000; 19: 187-95.
20. Whitney CG, Farley MM, Hadler J, et al., and the Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737-46.
21. Dagan R. Pneumococcal conjugate vaccines probe studies: the solution points to the problem. Adv Exp Med Biol 2009; 634: 69-77.
22. Hansen J, Black S, Shinefield H., et al Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J 2006; 25: 779-81.
23. O'Brien K.L., Moulton LH, Reid R, et al Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 2003; 362: 355-61.
24. Lucero MG, Dulalia VE, Nillos L.T., et al Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev 2009; 4: CD004977.
25. Lucero MG, Nohynek H, Williams G., et al Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial. Pediatr Infect Dis J 2009; 28: 455-62.
26. Eskola J, Kilpi T, Palmu A., et al, and the Finnish Otitis Media Study Group. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344: 403-09.
27. Goldblatt D, Hussain M, Andrews N., et al Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. J Infect Dis 2005; 192: 387-93.
28. Arnoux S, Weinberger C, Gessner BD Vaccine-preventable influenza disease burden from clinical trials of Vaxigrip - an inactivated split virion influenza vaccine - supports wider vaccine use. Vaccine 2007; 25: 7720-31.
29. Phrommintikul A, Kuanprasert S, Wongcharoen W., Kanjanavanit R, Chaiwarith R, Sukonthasarn A. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J 2011; 32: 1730-35.
30. Zaman K, Roy E, Arifeen S.E., et al Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008; 359: 1555-64.
31. Leino T, Ollgren J, Salo H., Tiihonen P, Kilpi T. First year experience of rotavirus immunisation programme in Finland. Vaccine 2012; 31: 176-82.
32. Meeting of the immunization Strategic Advisory Group of Experts, April 2009 - conclusions and recommendations. Wkly Epidemiol Rec 2009; 84: 220-36.
33. Armah GE, Sow SO, Breiman R.F., et al Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376: 606-14.
34. Feikin DR, Laserson KF, Ojwando J, et al Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya. Vaccine 2012; 30 (suppl 1): A52-60.
35. Madhi SA, Cunliffe NA, Steele D, et al Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010; 362: 289-98.
36. Cunnington AJ, de Souza JB, Walther M, Riley EM Malaria impairs resistance to Salmonella through heme- and heme oxygenase-dependent dysfunctional granulocyte mobilization. Nat Med 2012; 18: 120-27.
37. Hament JM, Kimpen JL, Fleer A, Wolfs TF Respiratory viral infection predisposing for bacterial disease: a concise review. FEMS Immunol Med Microbiol 1999; 26: 189-95.
38. Madhi SA, Klugman KP, and the Vaccine Trialist Group. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004; 10: 811-13.
39. Shann F, Gratten M, Germer S., Linnemann V, Hazlett D, Payne R. Aetiology of pneumonia in children in Goroka Hospital, Papua New Guinea. Lancet 1984; 2: 537-41.
40. Klugman KP, Madhi SA Pneumococcal vaccines and flu preparedness. Science 2007; 316: 49-50.
41. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 2006; 19: 571-82.
42. Moore DP, Dagan R, Madhi SA Respiratory viral and pneumococcal coinfection of the respiratory tract: implications of pneumococcal vaccination. Expert Rev Respir Med 2012; 6: 451-65.
43. Moore DP, Klugman KP, Madhi SA Role of Streptococcus pneumoniae in hospitalization for acute community-acquired pneumonia associated with culture-confirmed Mycobacterium tuberculosis in children: a pneumococcal conjugate vaccine probe study. Pediatr Infect Dis J 2010; 29: 1099-104.
44. Agnandji S.T., Lell B, Fernandes J.F., et al, and the RTS, S Clinical Trials Partnership. A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N Engl J Med 2012; 367: 2284-95.
45. Agnandji S.T., Lell B, Soulanoudjingar S.S., et al, and the RTS, S Clinical Trials Partnership. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N Engl J Med 2011; 365: 1863-75.
46. Cheung YB, Xu Y, Tan S.H., Cutts F., Milligan P. Estimation of intervention effects using first or multiple episodes in clinical trials: The Andersen-Gill model re-examined. Stat Med 2010; 29: 328-36.
47. Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005; 54: 893-97.
48. Aaby P, Benn CS Non-specific and sex-differential effects of routine vaccines: what evidence is needed to take these effects into consideration in low-income countries? Hum Vaccin 2011; 7: 120-24.
49. Gupta M, Kumar R, Deb A.K., et al, and the Hib study working group. Multicenter surveillance for pneumonia & meningitis among children (<2 yr) for Hib vaccine probe trial preparation in India. Indian J Med Res 2010; 131: 649-58.
50. Ferdinands JM, Gargiullo P, Haber M., Moore M, Belongia EA, Shay DK Inactivated influenza vaccines for prevention of community-acquired pneumonia: the limits of using nonspecific outcomes in vaccine effectiveness studies. Epidemiology 2013; 24: 530-37.
51. Gessner BD, Brooks WA, Neuzil K.M., et al Vaccines as a tool to estimate the burden of severe influenza in children of low-resourced areas (November 30-December 1, 2012, Les Pensieres, Veyrier-du-Lac, France). Vaccine 2013; 31: 3222-28.
52. Scott JA, Berkley JA, Mwangi I, et al Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. Lancet 2011; 378: 1316-23.